AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15698707 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance assessments during quiet standing (feet together eyes open, feet together eyes closed, single limb stance eyes open)
Number of subjects: 97
Study 15698707 — intervention group
Group type: EXPERIMENTAL
Intervention: Data normalized for height
Number of subjects: 97
Study 15698707 — intervention group
Group type: EXPERIMENTAL
Intervention: Single limb stance trials
Number of subjects: 97
Study 12681877 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of doxycycline orally twice a day for 7 days
Number of subjects: 800
Study 12681877 — intervention group
Group type: COMPARATOR
Intervention: 100 mg of doxycycline orally twice a day for 3 days followed by an oral placebo twice daily for the last 4 days
Number of subjects: 800
Study 10389286 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg) every day for six months
Number of subjects: 40
Study 10389286 — intervention group
Group type: COMPARATOR
Intervention: Premarin (0.625 mg) every day plus Provera (5 mg) from day 1 to day 12 every month for six months
Number of subjects: 40
Study 8684694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel (0.5 mg) for cervical ripening and intravaginal PGE2 gel (2 mg) for induction of labor
Number of subjects: 75
Study 8684694 — intervention group
Group type: COMPARATOR
Intervention: i.v. Oxytocin+Amniotomy for induction of labor
Number of subjects: 75
Study 1880796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (50 mg/kg/day)
Number of subjects: 31
Study 1880796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7035184 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg b.i.d.
Number of subjects: 9
Study 7035184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30890197 — intervention group
Group type: EXPERIMENTAL
Intervention: Amber lenses intervention (to block blue light)
Number of subjects: 14
Study 30890197 — intervention group
Group type: COMPARATOR
Intervention: Clear lenses intervention (control)
Number of subjects: 14
Study 29045610 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I concentration above the upper reference limit (URL)
Number of subjects: 4748
Study 29045610 — intervention group
Group type: COMPARATOR
Intervention: Troponin concentrations < URL
Number of subjects: 4748
Study 29045610 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding troponin to a model with demographic, cardiovascular risk factor, and clinical variables
Number of subjects: 4748
Study 27091008 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 2493
Study 27091008 — intervention group
Group type: COMPARATOR
Intervention: Injectable progestin contraception (IPC)
Number of subjects: 2493
Study 24678280 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (1 g daily for 4 weeks)
Number of subjects: 30
Study 24678280 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched control for 4 weeks)
Number of subjects: 30
Study 22646140 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of intravenous proton pump inhibitors (PPIs)
Number of subjects: 875
Study 22646140 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intensive intravenous regimen of PPIs
Number of subjects: 875
Study 22646140 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of intravenous PPIs
Number of subjects: 875
Study 22646140 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy
Number of subjects: 875
Study 22646140 — intervention group
Group type: COMPARATOR
Intervention: Late endoscopy
Number of subjects: 875
Study 20219293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chestnut's Bloomington Outpatient Treatment (CBOP) without ACC
Number of subjects: 320
Study 20219293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chestnut's Bloomington Outpatient Treatment (CBOP) with ACC
Number of subjects: 320
Study 20219293 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) without ACC
Number of subjects: 320
Study 20219293 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) with ACC
Number of subjects: 320
Study 17980528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bu‐zhong‐yi‐qi‐tang
Number of subjects: 60
Study 17980528 — intervention group
Group type: COMPARATOR
Intervention: Ping‐wei‐san
Number of subjects: 60
Study 15901745 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (PG) intravenous infusion
Number of subjects: 36
Study 15901745 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 36
Study 12468601 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter (40 g fat)
Number of subjects: 10
Study 12468601 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (40 g fat)
Number of subjects: 10
Study 12468601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (40 g fat)
Number of subjects: 10
Study 12468601 — intervention group
Group type: COMPARATOR
Intervention: No-fat test meal (0 g fat)
Number of subjects: 10
Study 12084522 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation in group 1 (14 patients)
Number of subjects: 31
Study 12084522 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation in group 2 (9 patients)
Number of subjects: 31
Study 12084522 — intervention group
Group type: COMPARATOR
Intervention: Hyperventilation in group 3 (8 patients)
Number of subjects: 31
Study 12084522 — intervention group
Group type: COMPARATOR
Intervention: Naloxone administration
Number of subjects: 31
Study 9793768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.02% solution, applied for 3 minutes)
Number of subjects: 17
Study 9793768 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical excision only)
Number of subjects: 17
Study 7867870 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 80 mg, three times daily for 8 days
Number of subjects: 32
Study 7867870 — intervention group
Group type: COMPARATOR
Intervention: High fibre diet
Number of subjects: 32
Study 7867870 — intervention group
Group type: COMPARATOR
Intervention: Intracellular fat
Number of subjects: 32
Study 2916939 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection with postoperative treatment of fluorouracil and hepatic irradiation
Number of subjects: 356
Study 2916939 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection only (observation)
Number of subjects: 356
Study 2916939 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 356
Study 356249 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 25 mg t.i.d. for 14 days
Number of subjects: 120
Study 356249 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg b.i.d. for 14 days
Number of subjects: 120
Study 31719214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis MB40 at 5 × 10^9 CFU once daily for 4 weeks
Number of subjects: 100
Study 31719214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis MB40
Number of subjects: 100
Study 31719214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31279724 — intervention group
Group type: EXPERIMENTAL
Intervention: National College Health Assessment (N = 610,543)
Number of subjects: 788235
Study 31279724 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Minds Study (N = 177,692)
Number of subjects: 788235
Study 31279724 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger, low flourishing, and suicide plans (assessed in only one dataset)
Number of subjects: 788235
Study 27910718 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% CHO/45% fat diet (higher fat diet)
Number of subjects: 0
Study 27910718 — intervention group
Group type: COMPARATOR
Intervention: 60% CHO/25% fat diet (lower fat diet)
Number of subjects: 0
Study 25979191 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Number of subjects: 75
Study 25979191 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 75
Study 25979191 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphysis group
Number of subjects: 75
Study 25979191 — intervention group
Group type: COMPARATOR
Intervention: Ramus group
Number of subjects: 75
Study 25979191 — intervention group
Group type: EXPERIMENTAL
Intervention: Both harvesting techniques
Number of subjects: 75
Study 23931537 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak intervention (hints with 66% of incorrect interpretations and 33% of correct interpretations)
Number of subjects: 117
Study 23931537 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong intervention (hints with 80% of incorrect interpretations and 20% of correct interpretations)
Number of subjects: 117
Study 23931537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hints)
Number of subjects: 117
Study 23931537 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak and strong intervention groups (combined)
Number of subjects: 117
Study 23931537 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 117
Study 21303619 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor during the intervention period
Number of subjects: 10
Study 21303619 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABTel telemedicine system
Number of subjects: 10
Study 19522369 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic foam cushions (5 different types tested)
Number of subjects: 35
Study 17093179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) breakfast
Number of subjects: 8
Study 17093179 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) breakfast
Number of subjects: 8
Study 14977667 — intervention group
Group type: COMPARATOR
Intervention: No preconditioning (group 1)
Number of subjects: 42
Study 14977667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic preconditioning (group 2)
Number of subjects: 42
Study 14977667 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric preconditioning (group 3)
Number of subjects: 42
Study 14977667 — intervention group
Group type: COMPARATOR
Intervention: Isometric preconditioning (80 N) for AT and HT grafts alone (no fixation)
Number of subjects: 42
Study 11708938 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 20
Study 11708938 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 9257670 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day)
Number of subjects: 43
Study 9257670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (8 hours/day i.v. infusion)
Number of subjects: 43
Study 9257670 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet medication (Control)
Number of subjects: 43
Study 8217179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 0.03 mg/kg
Number of subjects: 69
Study 8217179 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 69
Study 3620398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin protocol
Number of subjects: 60
Study 3620398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin protocol
Number of subjects: 60
Study 3620398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxytocin)
Number of subjects: 60
Study 31623764 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 4146
Study 31623764 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 4146
Study 30018242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 13
Study 30018242 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 13
Study 27195814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (SBP target <120 mm Hg, n=1317)
Number of subjects: 2636
Study 27195814 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (SBP target <140 mm Hg, n=1319)
Number of subjects: 2636
Study 27195814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 2636
Study 27195814 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 2636
Study 24968148 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μM capsaicin
Number of subjects: 20
Study 24968148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia severity
Number of subjects: 20
Study 23241939 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin and rutin
Number of subjects: 10
Study 23241939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20523971 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g glucose administration
Number of subjects: 0
Study 20523971 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose administration
Number of subjects: 0
Study 18554201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection Fraction ≤ 35%
Number of subjects: 1135
Study 18554201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection Fraction 36-49%
Number of subjects: 1135
Study 18554201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection Fraction ≥ 50%
Number of subjects: 1135
Study 15683479 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion
Number of subjects: 48
Study 15683479 — intervention group
Group type: COMPARATOR
Intervention: Monophasic cardioversion
Number of subjects: 48
Study 12586452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 0
Study 12586452 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine depletion
Number of subjects: 0
Study 12586452 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 0
Study 10773778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) - 8 1-hour sessions of individual cognitive therapy for 6 weeks, followed by 6 2-hour sessions of social skills training (SST) in group weekly
Number of subjects: 67
Study 10773778 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT) - after switching group 2 to CBT
Number of subjects: 67
Study 10773778 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (ST) - 12 weeks (6 half-hour sessions)
Number of subjects: 67
Study 8873158 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose neuraxis irradiation (3,600 cGy/20 fractions)
Number of subjects: 126
Study 8873158 — intervention group
Group type: COMPARATOR
Intervention: Reduced neuraxis irradiation (2,340 cGy/13 fractions)
Number of subjects: 126
Study 1736336 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily for 2 weeks
Number of subjects: 60
Study 1736336 — intervention group
Group type: COMPARATOR
Intervention: 300 mg ranitidine at bedtime for 2 weeks
Number of subjects: 60
Study 6093656 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (9 mg/kg)
Number of subjects: 18
Study 6093656 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study 6093656 — intervention group
Group type: COMPARATOR
Intervention: No active drug intervention
Number of subjects: 18
Study 3094459 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combining MMC with Tegaful
Number of subjects: 1156
Study 3094459 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic intravenous administration of MMC 4 mg, two times a week for three weeks, combined with prolonged oral administration of Tegaful 800 mg/day for more than three months
Number of subjects: 1156
Study 3094459 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative local intra vessel administration of MMC 10 mg
Number of subjects: 1156
Study 30571337 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural stroke
Number of subjects: 0
Study 30571337 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol myocardial infarction (MI)
Number of subjects: 0
Study 30571337 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-only event
Number of subjects: 0
Study 27182068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention (10 weeks, 45 min/week)
Number of subjects: 24
Study 27182068 — intervention group
Group type: COMPARATOR
Intervention: Active control (nondance program)
Number of subjects: 24
Study 25795413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 48
Study 25795413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral near-infrared spectroscopy (NIRS) oximetry plus a clinical treatment guideline
Number of subjects: 166
Study 23782447 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral ultrasound score
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Interburst intervals on an amplitude‐integrated electroencephalogram at 64 hours of life
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental outcome at 2 years corrected age
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging at term
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers at 6 and 64 hours after birth
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 166
Study 23782447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at term date
Number of subjects: 166
Study 20886791 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint sticking therapy (observation group)
Number of subjects: 73
Study 20886791 — intervention group
Group type: COMPARATOR
Intervention: Jiawei Mojie tablet (control group)
Number of subjects: 73
Study 18991816 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with target levels of glycemia (n=41)
Number of subjects: 81
Study 18991816 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients with 1% lowering of HbA1c (n=18)
Number of subjects: 81
Study 18991816 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients with HbA1c lowering < 1% (n=26)
Number of subjects: 81
Study 18991816 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients with increase of HbA1c (n=31)
Number of subjects: 81
Study 18991816 — intervention group
Group type: COMPARATOR
Intervention: Control group with usual treatment (n=40)
Number of subjects: 81
Study 16586308 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychiatric day hospital care
Number of subjects: 0
Study 16586308 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 0
Study 11821459 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day residential communication skills course
Number of subjects: 93
Study 9661554 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 5 mg
Number of subjects: 70
Study 9661554 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 7.5 mg
Number of subjects: 70
Study 9661554 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 10 mg
Number of subjects: 70
Study 9661554 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 12.5 mg
Number of subjects: 70
Study 9661554 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 15 mg
Number of subjects: 70
Study 9661554 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 30 mg
Number of subjects: 70
Study 9661554 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (control group)
Number of subjects: 70
Study 7947208 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied calcipotriol
Number of subjects: 6
Study 2534042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 2534042 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 2534042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2534042 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 0
Study 2534042 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 336653 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbuterol
Number of subjects: 15
Study 336653 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 15
Study 29420232 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 44
Study 29420232 — intervention group
Group type: COMPARATOR
Intervention: Skin incisions only (sham control)
Number of subjects: 44
Study 29420232 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 44
Study 29420232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 44
Study 26899531 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe-storage container plus water pasteurization indicator
Number of subjects: 210
Study 26899531 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe-storage container alone
Number of subjects: 210
Study 26899531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 24401291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g of bioactive collagen peptide (BCP) VERISOL® once daily for 8 weeks
Number of subjects: 114
Study 24401291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 24401291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g of bioactive collagen peptide (BCP) VERISOL® after 8 weeks
Number of subjects: 114
Study 24401291 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 8 weeks
Number of subjects: 114
Study 21207071 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month, facility- and home-based viniyoga intervention (n = 32)
Number of subjects: 63
Study 21207071 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 31)
Number of subjects: 63